NAMI

Nami Therapeutics is an innovative radiopharmaceutical company focused on developing tumor-specific precision therapeutics to treat cancer patients. Founded in 2018 as a spin-off from the University of Connecticut and the University of North Carolina, the company leverages a proprietary nanocarrier platform for the targeted delivery of radioisotopes. Its lead candidate, XLNT-1, consists of Holmium-166 loaded nanoparticles designed to treat peritoneal metastasis in ovarian cancer by providing localized radiation with minimal systemic exposure. The company's technology aims to improve survival rates for difficult-to-treat cancers through enhanced tumor penetration and scalable manufacturing processes. Nami is currently advancing its pipeline toward first-in-human clinical trials, supported by federal grants and academic partnerships.